3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Nasopharyngeal Carcinoma
7
Esophageal Squamous Cell Carcinoma
4
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
3
Colorectal Neoplasms
3
Carcinoma, Renal Cell
3
Carcinoma, Non-Small-Cell Lung
3
Advanced Solid Tumor
3
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Nasopharyngeal Neoplasms
2
Head and Neck Neoplasms
2
Breast Neoplasms
2
Advanced Breast Cancer
2
Urinary Bladder Neoplasms
1
Turcot syndrome
1
Solid Tumor
1
Skin Neoplasms
1
Sarcoma
1
Recurrence
1
Papillomavirus Infections
1
Pancreatic Neoplasms
1
Pancreatic Cancer Metastatic
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Muscle Invasive Bladder Cancer (MIBC)
1
Mouth Neoplasms
1
Meningeal Carcinomatosis
1
Interventions
Oxaliplatin
2
Capecitabine
2
toripalimab
1
tislelizumab
1
camrelizumab
1
Immune Checkpoint Inhibitors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Locally Advanced Rectal Cancer
×
toripalimab
×
90 days
×
Clear all
NCT06281405
2026-04-03
TORCH-iTNT
Fudan University
Phase 2
Recruiting
192 enrolled